| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on debt extinguishment | NaN | -1,965 | 0 | -17,930 |
| Net loss | -510 | 81,957 | 24,325 | -174,370 |
| Depreciation and amortization | 5,065 | 4,291 | 4,870 | 13,454 |
| Stock-based compensation expense | 15,872 | 13,367 | 13,655 | 42,984 |
| Non-cash operating lease expense | 1,323 | 1,262 | 1,387 | 2,936 |
| Amortization of debt discounts | 2,624 | 605 | 2,463 | 9,700 |
| Changes in fair value of financial instruments | 0 | -1 | -2,081 | -50,203 |
| Other | -214 | -428 | 443 | -1,231 |
| Accounts receivable | -21,623 | 91,021 | -24,192 | -37,040 |
| Supplies | 13,328 | 9,606 | 8,523 | 2,621 |
| Prepaid expenses and other current assets | 1,554 | 345 | 2,540 | 2,265 |
| Other assets | -153 | -374 | 660 | -334 |
| Accounts payable | 16,371 | 12,231 | 729 | -1,925 |
| Accrued expenses and other liabilities | -14,977 | 29,271 | 889 | -18,681 |
| Net cash provided by (used in) operating activities | 32,876 | 44,780 | 62,425 | -24,050 |
| Maturities of marketable securities | NaN | 0 | 0 | 0 |
| Purchases of marketable securities | NaN | 0 | NaN | NaN |
| Purchases of property and equipment | 10,342 | 5,090 | 7,095 | 4,075 |
| Net cash used in investing activities | -10,342 | -5,090 | -7,095 | -4,075 |
| Payments made on finance lease obligations | 40 | 39 | 23 | 44 |
| Proceeds from exercise of stock options | 920 | 3,862 | 1,151 | 2,624 |
| Repayment of the original term loans | NaN | 0 | NaN | NaN |
| Issuance of the 2025 warrants | NaN | 0 | 0 | 10,270 |
| Payment of third-party debt issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of preferred stock, net of issuance costs-Series EPreferred Stock | NaN | 0 | 0 | 87,637 |
| Payments of 2023 term loan amendment fee | NaN | 0 | 0 | 4,000 |
| Proceeds from the 2023 term loan, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | NaN | 0 | 0 | 528,459 |
| Proceeds from issuance of preferred stock, net of issuance costs-Series FPreferred Stock | NaN | 0 | 0 | 33,601 |
| Issuance of the 2025 convertible notes, net of issuance costs | NaN | 0 | 0 | 27,865 |
| Payment of taxes withheld from net settlement of exercised options and vested rsus | 56 | 333 | 16,560 | 1,658 |
| Payment of deferred offering costs | 0 | 0 | 5,665 | 2,045 |
| Repurchase of common stock | 0 | 91 | 0 | 22 |
| Net cash provided by financing activities | 824 | 3,399 | -21,097 | 682,687 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -10 | -29 | 62 | 97 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 23,348 | 43,060 | 34,295 | 654,659 |
| Cash, cash equivalents, and restricted cash at beginning of period | 800,042 | 756,982 | 68,028 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 823,390 | 800,042 | 756,982 | NaN |
Caris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. (CAI)